Compare NTES & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTES | REGN |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | China | United States |
| Employees | 25382 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.3B | 77.5B |
| IPO Year | N/A | 1995 |
| Metric | NTES | REGN |
|---|---|---|
| Price | $117.21 | $705.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 25 |
| Target Price | $160.00 | ★ $830.16 |
| AVG Volume (30 Days) | 558.7K | ★ 631.5K |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.61% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 6.75 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $9.57 | $12.45 |
| Revenue Next Year | $8.57 | $10.13 |
| P/E Ratio | ★ $79.88 | $101.40 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $103.23 | $476.49 |
| 52 Week High | $159.55 | $821.11 |
| Indicator | NTES | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 37.99 |
| Support Level | $108.71 | $689.88 |
| Resistance Level | $119.72 | $783.87 |
| Average True Range (ATR) | 2.02 | 18.92 |
| MACD | 0.25 | -5.59 |
| Stochastic Oscillator | 80.13 | 37.86 |
Founded in the late 1990s as an internet portal, NetEase has evolved into China's second-largest online gaming company. Its early success was anchored by the massively multiplayer online role-playing game Fantasy Westward Journey, which laid the foundation for a durable franchise strategy. Over the past decade, the company has expanded its portfolio with successful titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which continue to maintain sizable and engaged player bases.In addition to its in-house development capabilities, NetEase partners with global IP holders such as Microsoft and Marvel to develop and publish titles based on established franchises, including World of Warcraft, Diablo Immortal, and Marvel Rivals, further strengthening its global presence.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).